SG11201405578TA - Pharmaceutical composition containing peptide - Google Patents
Pharmaceutical composition containing peptideInfo
- Publication number
- SG11201405578TA SG11201405578TA SG11201405578TA SG11201405578TA SG11201405578TA SG 11201405578T A SG11201405578T A SG 11201405578TA SG 11201405578T A SG11201405578T A SG 11201405578TA SG 11201405578T A SG11201405578T A SG 11201405578TA SG 11201405578T A SG11201405578T A SG 11201405578TA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical composition
- composition containing
- containing peptide
- peptide
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012072352 | 2012-03-09 | ||
| PCT/JP2013/056429 WO2013133405A1 (en) | 2012-03-09 | 2013-03-08 | Pharmaceutical composition containing peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201405578TA true SG11201405578TA (en) | 2014-11-27 |
Family
ID=49116873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201405578TA SG11201405578TA (en) | 2012-03-09 | 2013-03-08 | Pharmaceutical composition containing peptide |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20150359864A1 (en) |
| EP (1) | EP2823824A4 (en) |
| JP (1) | JP6159996B2 (en) |
| KR (1) | KR20140138900A (en) |
| CN (1) | CN104168917A (en) |
| SG (1) | SG11201405578TA (en) |
| WO (1) | WO2013133405A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| JP6740127B2 (en) * | 2013-12-06 | 2020-08-12 | ザ・ブロード・インスティテュート・インコーポレイテッド | Formulation for neoplastic vaccine |
| EP3082853A2 (en) | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| CN112972378A (en) * | 2014-09-24 | 2021-06-18 | 艾瑞朗医疗公司 | Peptidomimetic macrocycles and formulations thereof |
| JP6781508B2 (en) * | 2014-11-18 | 2020-11-04 | 塩野義製薬株式会社 | Stabilized peptide composition |
| EP3234193B1 (en) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molecular biomarkers for cancer immunotherapy |
| EP3234130B1 (en) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Methods for profiling the t-cell- receptor repertoire |
| WO2016187508A2 (en) | 2015-05-20 | 2016-11-24 | The Broad Institute Inc. | Shared neoantigens |
| EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| WO2018212358A1 (en) * | 2017-05-19 | 2018-11-22 | 学校法人慶應義塾 | Peptide vaccine and peptide vaccine composition for cranial nerve disease |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4689833B2 (en) * | 1998-12-22 | 2011-05-25 | イーライ リリー アンド カンパニー | Storage-stable formulation of glucagon-like peptide-1 |
| PT1513934E (en) | 2002-06-06 | 2011-05-11 | Oncotherapy Science Inc | Genes and polypeptides relating to human colon cancers |
| JP4406607B2 (en) | 2002-08-26 | 2010-02-03 | オンコセラピー・サイエンス株式会社 | Peptide and pharmaceutical containing the same |
| EP2267022B1 (en) | 2002-09-12 | 2015-02-11 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| PT1620456E (en) * | 2003-04-18 | 2014-04-15 | Biotech Synergy Inc | TUMOR-ASSOCIATED HLA-A2 ANTIGENIC PEPTIDES AND THEIR COMPOSITIONS |
| WO2006090810A2 (en) * | 2005-02-25 | 2006-08-31 | Oncotherapy Science, Inc. | Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides |
| PL1855707T3 (en) * | 2005-02-28 | 2012-08-31 | Oncotherapy Science Inc | Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides |
| BRPI0613970B8 (en) | 2005-07-27 | 2021-05-25 | Oncotherapy Science Inc | composition for the treatment or prevention of colon cancer comprises a pharmaceutically effective amount of a sirna against a 34-tone polynucleotide |
| AU2006277295B2 (en) | 2005-08-09 | 2011-08-11 | Oncotherapy Science, Inc. | Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same |
| CN101108869B (en) * | 2006-07-21 | 2010-06-02 | 海南德泽药物研究有限公司 | Mangiferin salt and method of preparing the same and use thereof |
| CA2667030C (en) * | 2006-10-17 | 2016-03-15 | Oncotherapy Science, Inc. | Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides |
| JP2008127283A (en) * | 2006-11-16 | 2008-06-05 | Biseibutsu Kagaku Kenkyusho:Kk | Feline infectious peritonitis vaccine |
| GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| TWI438207B (en) * | 2007-02-21 | 2014-05-21 | Oncotherapy Science Inc | Peptide vaccine for cancers exhibiting tumor-associated antigens |
| MX2009012964A (en) * | 2007-06-01 | 2010-01-14 | Acologix Inc | High temperature stable peptide formulation. |
| CN101835792B (en) | 2007-08-20 | 2015-04-15 | 肿瘤疗法科学股份有限公司 | FOXM1 peptides and agents comprising FOXM1 peptides |
| WO2009025117A1 (en) | 2007-08-20 | 2009-02-26 | Oncotherapy Science, Inc. | Cdca1 peptide and pharmaceutical agent comprising the same |
| WO2009131995A1 (en) * | 2008-04-21 | 2009-10-29 | Nanobio Corporation | Nanoemulsion influenza vaccine |
| DE602008000891D1 (en) * | 2008-04-30 | 2010-05-12 | Immatics Biotechnologies Gmbh | Novel formulations of tumor-associated peptides which bind to human leukocyte antigens of class I or II for vaccination |
| TW201000119A (en) | 2008-06-10 | 2010-01-01 | Oncotherapy Science Inc | MYBL2 epitope peptides and vaccines containing the same |
| TWI526219B (en) | 2008-06-19 | 2016-03-21 | 腫瘤療法 科學股份有限公司 | Cdca1 epitope peptides and vaccines containing the same |
| TWI466680B (en) | 2008-08-01 | 2015-01-01 | Oncotherapy Science Inc | MELK epitope peptide and vaccine containing the peptide |
| TW201008574A (en) * | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| CN102264897B (en) | 2008-10-22 | 2014-06-11 | 肿瘤疗法科学股份有限公司 | RAB6KIFL/KIF20A epitope peptide and vaccine comprising it |
| TWI500932B (en) | 2008-12-05 | 2015-09-21 | Oncotherapy Science Inc | WDRPUH epitope peptide and vaccine containing the peptide |
| TW201032820A (en) | 2008-12-16 | 2010-09-16 | Oncotherapy Science Inc | ELOVL7 epitope peptides and vaccines containing the same |
| MX2011006755A (en) | 2008-12-24 | 2011-07-20 | Oncotherapy Science Inc | C1orf59 peptides and vaccines including the same. |
| TWI469791B (en) | 2009-02-18 | 2015-01-21 | Oncotherapy Science Inc | Foxm1 peptides and vaccines containing the same |
| JP2012519470A (en) | 2009-03-04 | 2012-08-30 | オンコセラピー・サイエンス株式会社 | VANGL1 peptide and vaccine containing the same |
| WO2010106770A1 (en) | 2009-03-18 | 2010-09-23 | Oncotherapy Science, Inc. | Neil3 peptides and vaccines including the same |
| TW201124530A (en) | 2009-12-01 | 2011-07-16 | Oncotherapy Science Inc | IMP-3 oligopeptides and vaccines including the same |
| TWI485245B (en) | 2010-01-25 | 2015-05-21 | Oncotherapy Science Inc | Modified MELK peptide and vaccine containing the same |
| CA2857502C (en) * | 2011-11-30 | 2019-08-13 | 3M Innovative Properties Company | Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same |
-
2013
- 2013-03-08 WO PCT/JP2013/056429 patent/WO2013133405A1/en active Application Filing
- 2013-03-08 KR KR20147028433A patent/KR20140138900A/en not_active Withdrawn
- 2013-03-08 JP JP2013046756A patent/JP6159996B2/en active Active
- 2013-03-08 SG SG11201405578TA patent/SG11201405578TA/en unknown
- 2013-03-08 US US14/383,854 patent/US20150359864A1/en not_active Abandoned
- 2013-03-08 EP EP13757952.0A patent/EP2823824A4/en not_active Withdrawn
- 2013-03-08 CN CN201380013184.9A patent/CN104168917A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013133405A1 (en) | 2013-09-12 |
| CN104168917A (en) | 2014-11-26 |
| KR20140138900A (en) | 2014-12-04 |
| EP2823824A4 (en) | 2015-09-16 |
| JP2013213031A (en) | 2013-10-17 |
| JP6159996B2 (en) | 2017-07-12 |
| EP2823824A1 (en) | 2015-01-14 |
| US20150359864A1 (en) | 2015-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP3864A (en) | Pharmaceutical composition | |
| PL3181122T3 (en) | Dasatinib pharmaceutical composition | |
| ZA201501930B (en) | Pharmaceutical composition | |
| ZA201503594B (en) | Pharmaceutical compositions | |
| GB201118232D0 (en) | Pharmaceutical composition | |
| SG11201405578TA (en) | Pharmaceutical composition containing peptide | |
| EP2832730A4 (en) | Mirabegron-containing pharmaceutical composition | |
| IL266415A (en) | Novel pharmaceutical composition | |
| PT2815752T (en) | Oral pharmaceutical composition | |
| ZA201308157B (en) | Pharmaceutical composition | |
| EP2727593A4 (en) | Nicorandil-containing pharmaceutical composition | |
| EP2711010A4 (en) | Pharmaceutical composition | |
| ZA201502987B (en) | Pharmaceutical composition | |
| SI2638894T1 (en) | Pharmaceutical composition containing phospholipid | |
| HUP1100444A2 (en) | Pharmaceutical composition | |
| GB201211153D0 (en) | Pharmaceutical compositions | |
| HUP1100445A2 (en) | Pharmaceutical composition | |
| ZA201406407B (en) | Pharmaceutical formulation containing flupirtin | |
| ZA201400751B (en) | Pharmaceutical composition | |
| IL238075A0 (en) | Pharmaceutical compositions | |
| GB201221130D0 (en) | New pharmaceutical composition | |
| GB201207628D0 (en) | New pharmaceutical composition | |
| GB201207701D0 (en) | New pharmaceutical composition | |
| GB201219234D0 (en) | Pharmaceutical compositions | |
| GB201213303D0 (en) | Pharmaceutical compositions |